Nonsteroidal anti-inflammatory drugs (NSAIDs) are a group of heterogeneous drugs largely known for their anti-inflammatory, antipyretic, and analgesic effects, which are met by means of the inhibition of the cyclooxygenase (COX) enzymes. Even when their use in patients with diabetes mellitus is limited due to relevant adverse events, some pharmacological and metabolic effects of NSAIDs have been further studied to be potentially beneficial in the prevention and/or treatment of diabetic subjects. Effects on endogenous glucose production, peripheral insulin resistance, pancreatic islet, and systemic inflammation and the insulin clearance have been reported. In this article, we overview the scientific literature of the last 5 years regarding the potential effects of NSAID treatment on diabetes prevention/treatment. The selected papers showed information in both humans and animal models. Furthermore, we included papers that suggest new areas for further investigation, and we discussed our own suggestions on this matter.
ChandrasekharanNVDaiHRoosKL. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002;99(21):13926–13931.
2.
RaoPKnausEE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 2008;11(2):81s–110s.
3.
BastardJPMaachiMLagathuC. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4–12.
4.
KingGL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol. 2008;79(8 suppl):1527–1534.
5.
SchmidtMIDuncanBBSharrettAR. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999;353(9165):1649–1652.
6.
PradhanADMansonJERifaiN. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327–334.
7.
DonathMYDalmasÉSauterNS. Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity. Cell Metab. 2013;17(6):860–872.
8.
OgataAMorishimaAHiranoT. Improvement of HbA1c during treatment with humanised antiinterleukin 6 receptor antibody tocilizumab. Ann Rheum Dis. 2011;70(6):1164–1165.
9.
EsserNPaquotNScheenAJ. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opin Investig Drugs. 2015;24(3):283–307.
10.
KotasMEGoreckiMCGillumMP. Sirtuin-1 is a nutrient-dependent modulator of inflammation. Adipocyte. 2013;2(2):113–118.
11.
HameedIMasoodiSRMirSA. Type 2 diabetes mellitus: from a metabolic disorder to an inflammatory condition. World J Diabetes. 2015;6(4):598–612.
12.
LarsenCMFaulenbachMVaagA. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care. 2009;32(9):1663–1668.
13.
GonzálezCDLeeMSMarchettiP. The emerging role of autophagy in the pathophysiology of diabetes mellitus. Autophagy. 2011;7(1):2–11.
14.
KitamuraT. The role of FOXO1 in β-cell failure and type 2 diabetes mellitus. Nat Rev Endocrinol. 2013;9(10):615–623.
15.
Mothe-SatneyIFillouxCAmgharH. Adipocytes secrete leukotrienes: contribution to obesity-associated inflammation and insulin resistance in mice. Diabetes. 2012;61(9):2311–2319.
16.
NeelsJG. A role for 5-lipoxygenase products in obesity-associated inflammation and insulin resistance. Adipocyte. 2013;2(4):262–265.
17.
Di GirolamoGFarinaMRiberioML. Effects of cyclooxygenase inhibitor pretreatment on nitric oxide production, nNOS and iNOS expression in rat cerebellum. Br J Pharmacol. 2003;139(6):1164–1170.
18.
Di GirolamoGFranchiADe Los SantosAR. Acción de los antiinflamatorios no esteroideos sobre la actividad de la lipooxigenasa y la ciclooxigenasa colónica de pacientes con neoplasia de colon. Medicina (B Aires). 2001;61(5 pt 1):566–572.
19.
KramerEHSassettiBKaminkerAJ. Effects of lysine clonixinate on platelet function. Comparison with other non-steroidal anti-inflammatory agents. Medicina (B Aires). 2001;61(3):301–307.
20.
FranchiADi GirolamoGFarinaM. In vivo and in vitro effects of lysine clonixinate on nitric oxide synthase in LPS-treated and untreated rat lung preparations. Nitric Oxide. 2001;5(2):150–157.
21.
FleischmanAShoelsonSEBernierR. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008;31(2):289–294.
22.
KoskaJOrtegaEBuntJC. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double blind placebo-controlled study. Diabetologia. 2009;52(3):385–393.
23.
GoldfineABFonsecaVJablonskiKA. Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2013;159(1):1–12.
24.
FaghihimaniEAminorroayaARezvanianH. Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes. Acta Diabetol. 2013;50(4):537–543.
25.
FaghihimaniEAminorroayaARezvanianH. Reduction of insulin resistance and plasma glucose level by salsalate treatment in persons with prediabetes. Endocr Pract. 2012;18(6):826–833.
26.
KimSHLiuAArielD. Effect of salsalate on insulin action, secretion, and clearance in nondiabetic, insulin-resistant individuals: a randomized, placebo-controlled study. Diabetes Care. 2014;37(7):1944–1950.
27.
BarzilayJIJablonskiKAFonsecaV. TINSAL-T2D Research Consortium. The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes. Diabetes Care. 2014;37(4):1083–1091.
28.
GoldfineABBuckJSDesouzaC; TINSAL-FMD (Targeting Inflammation Using Salsalate in Type 2 Diabetes–Flow-Mediated Dilation) Ancillary Study Team. Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD). Diabetes Care. 2013;36(12):4132–4139.
29.
FangFLuYMaDL. A meta-analysis of salicylates for type 2 diabetes mellitus. J Huazhong Univ Sci Technolog Med Sci. 2013;33(1):1–14.
30.
PenesovaAKoskaJOrtegaE. Salsalate has no effect on insulin secretion but decreases insulin clearance: a randomized, placebo-controlled trial in subjects without diabetes. Diabetes Obes Metab. 2015;17(6):608–612.
31.
AldereteTLSattlerFRRicheyJM. Salsalate treatment improves glycemia without altering adipose tissue in nondiabetic obese Hispanics. Diabetes Obes Metab. 2015;17(6):608–612.
32.
MotawiTMBustanjiYEl-MaraghySA. Naproxen and cromolyn as new glycogen synthase kinase 3β inhibitors for amelioration of diabetes and obesity: an investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation. J Biochem Mol Toxicol. 2013;27(9):425–436.
33.
SungKCKimSH. Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. J Clin Endocrinol Metab. 2011;96(4):1093–1097.
34.
TargherGByrneCD. Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab. 2013;98(2):483–495.
35.
BrennerCGalluzziLKeppO. Decoding cell death signals in liver inflammation. J Hepatol. 2013;59(3):583–594.
36.
ChaiWLiuJJahnLA. Salsalate attenuates free fatty acid-induced microvascular and metabolic insulin resistance in humans. Diabetes Care. 2011;34(7):1634–1638.
37.
NixonMWakeDJLivingstoneDE. Salicylate downregulates 11β-HSD1 expression in adipose tissue in obese mice and in humans, mediating insulin sensitization. Diabetes. 2012;61(4):790–796.
38.
DavisSNGrannerDK. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: HardmanJGLimbirdLE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill; 2001:1679–1714.
39.
RobertsLJMorrowJD. Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In: HardmanJGLimbirdLE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill; 2001:687–731.
40.
El-SeragHBHampelHJavadiF. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4(3):369–380.
41.
WuCYChenYJHoHJ. Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection. JAMA. 2012;308(18):1906–1914.
42.
YehCCLinJTJengLB. Nonsteroidal anti-inflammatory drugs are associated with reduced risk of early hepatocellular carcinoma recurrence after curative liver resection: a nationwide cohort study. Ann Surg. 2015;261(3):521–526.
43.
SethiAParmarHSKumarA. The effect of aspirin on atherogenic diet-induced diabetes mellitus. Basic Clin Pharmacol Toxicol. 2011;108(6):371–377.
44.
SunXHanFYiJ. Effect of aspirin on the expression of hepatocyte NF-κB and serum TNF-α in streptozotocin-induced type 2 diabetic rats. J Korean Med Sci. 2011;26(6):765–770.
45.
MuraliGMilneGLWebbCD. Fish oil and indomethacin in combination potently reduce dyslipidemia and hepatic steatosis in LDLR(-/-) mice. J Lipid Res. 2012;53(10):2186–2197.
46.
TianFZhangYJLiY. Celecoxib ameliorates non-alcoholic steatohepatitis in type 2 diabetic rats via suppression of the non-canonical Wnt signaling pathway expression. PLoS One. 2014;9(1):e83819.
47.
BahdeRKapoorSGuptaS. Nonselective inhibition of prostaglandin-endoperoxide synthases by naproxen ameliorates acute or chronic liver injury in animals. Exp Mol Pathol. 2014;96(1):27–35.
48.
SahasrabuddheVVGunjaMZGraubardBI. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst. 2012;104(23):1808–1814.
49.
GoldfineABFonsecaVJablonskiKA; TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2010;152(6):346–357.
50.
HuangHLLiuCTChouMC. Noni (Morinda citrifolia L.) Fruit Extracts Improve colon microflora and exert anti-inflammatory activities in Caco-2 cells. J Med Food. 2015;18(6):663–676.
51.
HuPThinschmidtJSCaballeroS. Loss of survival factors and activation of inflammatory cascades in brain sympathetic centers in type 1 diabetic mice. Am J Physiol Endocrinol Metab. 2015;308(8):e688–e698.doi:10.1152/ajpendo.00504.2014.
